Cargando…

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss

OBJECTIVE: To explore the effects of anti-tumour necrosis factor (TNF)α antibody therapy on bone mineral density (BMD) of the lumbar spine and femur neck in patients with rheumatoid arthritis (RA). METHODS: A total of 50 patients with active RA (DAS28⩾3.2) who started adalimumab (40 mg subcutaneousl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wijbrandts, C A, Klaasen, R, Dijkgraaf, M G W, Gerlag, D M, van Eck-Smit, B L F, Tak, P P
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2008
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945478/ https://www.ncbi.nlm.nih.gov/pubmed/18408246 http://dx.doi.org/10.1136/ard.2008.091611

Ejemplares similares

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis
por: Klaasen, R., et al.
Publicado: (2012)

Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study
por: Hoff, M, et al.
Publicado: (2008)

Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis
por: Wijbrandts, C A, et al.
Publicado: (2008)

Bone mineral density in patients with Juvenile Rheumatoid Arthritis
por: Zhizho, Ye, et al.
Publicado: (2008)

Monocyte Scintigraphy in Rheumatoid Arthritis: The Dynamics of Monocyte Migration in Immune-Mediated Inflammatory Disease
por: Thurlings, Rogier M., et al.
Publicado: (2009)

Rheumatoid arthritis in tight disease control is no longer risk of bone mineral density loss
por: Yoshii, Ichiro, et al.
Publicado: (2020)

TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade
por: van Kuijk, A W R, et al.
Publicado: (2009)

Rheumatoid arthritis and risk factors for low bone mineral density
por: Arinoviche, R
Publicado: (2004)

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis
por: Amkreutz, Josephine A. M. P., et al.
Publicado: (2021)

Reference values for bone density and bone mineral content from 5 to 80 years old in a province of Chile
por: Cossio-Bolanos, Marco, et al.
Publicado: (2022)

Interaction effects of significant risk factors on low bone mineral density in ankylosing spondylitis
por: Sun, Wenting, et al.
Publicado: (2023)

Bone Mineral Density Changes in Patients with Recent-Onset Rheumatoid Arthritis
por: Hafez, Eman A., et al.
Publicado: (2011)

Bone mineral density status in patients with recent-onset rheumatoid arthritis
por: Ketabforoush, Arsh Haj Mohamad Ebrahim, et al.
Publicado: (2023)

Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy
por: Marotte, Hubert, et al.
Publicado: (2008)

Bone mineral density loss in postmenopausal onset rheumatoid arthritis is not greater than premenopausal onset disease
por: Heidari, Behzad, et al.
Publicado: (2014)

Soluble Biomarkers of Cartilage and Bone Metabolism in Early Proof of Concept Trials in Psoriatic Arthritis: Effects of Adalimumab Versus Placebo
por: van Kuijk, Arno W. R., et al.
Publicado: (2010)

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue
por: van Kuijk, A W R, et al.
Publicado: (2008)

Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study
por: Hoff, Mari, et al.
Publicado: (2011)

Sex differences in frailty and its association with low bone mineral density in rheumatoid arthritis
por: Wysham, Katherine D., et al.
Publicado: (2020)

Smoking and overweight determine the likelihood of developing rheumatoid arthritis
por: de Hair, Maria J H, et al.
Publicado: (2013)

Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
por: Takahashi, Kengo, et al.
Publicado: (2015)

Bone mineral density in children with systemic lupus erythematosus and juvenile rheumatoid arthritis
por: Kashef, Sara, et al.
Publicado: (2007)

Bone mineral density and fractures in patients with rheumatoid arthritis: the DXA-HIP project
por: Ebrahimiarjestan, Mina, et al.
Publicado: (2023)

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2017)

Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density
por: Klop, Corinne, et al.
Publicado: (2016)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Impact of Treat-to-Target Therapy on Bone Mineral Density Loss in Patients With Rheumatoid Arthritis: A Prospective Cohort Study
por: Huang, Hong, et al.
Publicado: (2022)

Effect of Vitamin D Supplementation on Bone Mineral Density in Rheumatoid Arthritis Patients With Osteoporosis
por: Kwon, Oh Chan, et al.
Publicado: (2020)

Changes in bone mineral density over 10 years in patients with early rheumatoid arthritis
por: Theander, Lisa, et al.
Publicado: (2020)

The Influence of Menopause and Inflammation on Redox Status and Bone Mineral Density in Patients with Rheumatoid Arthritis
por: Stojanovic, Aleksandra, et al.
Publicado: (2021)

Anti-TNF Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by Which Anti-TNF Might Reduce Inflammation
por: Herenius, Marieke M. J., et al.
Publicado: (2013)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

Ghrelin plasma levels, gastric ghrelin cell density and bone mineral density in women with rheumatoid arthritis
por: Maksud, F.A.N., et al.
Publicado: (2017)

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
por: Visvanathan, S, et al.
Publicado: (2008)

Pathomechanisms of bone loss in rheumatoid arthritis
por: Sakthiswary, Rajalingham, et al.
Publicado: (2022)

Relationship between bone mineral density and anti-citrullinated protein antibody and rheumatoid factor in patients with rheumatoid arthritis
por: Sargın, Gökhan, et al.
Publicado: (2019)

Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis
por: Güler-Yüksel, Melek, et al.
Publicado: (2010)

Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
por: Suzuki, Takako, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0d6hm1inhu1460pckmdjmal9k3